A Food and Drug Administration advisory panel unanimously agreed yesterday that MedImmune's nasal flu vaccine FluMist worked in children under age 5, but it had a decidedly mixed opinion on whether the product was safe enough for children younger than 2. -
FDA Panel Supports Expanded FluMist Use
A Food and Drug Administration advisory panel unanimously agreed yesterday that MedImmune's nasal flu vaccine FluMist worked in children under age 5, but it had a decidedly mixed opinion on whether the product was safe enough for children younger than 2.-
By Michael S. Rosenwald